Relief in One Reach.™
RedeDose combines medication and water in a single, patented package—delivering complete relief exactly when and where you need it. We're disrupting the $40B+ OTC market with a product designed for modern, mobile consumers.
$40B+
Market Opportunity
5
Patents Issued
67%
Gross Margin
Millions Caught Without Complete Relief
Every day, millions of travelers, commuters, and consumers face a frustrating reality: when a headache, allergy attack, or motion sickness strikes on-the-go, they must buy both medicine and a separate beverage.
Of consumers now buy OTC medication only "as needed"
U.S. adults suffer from severe headaches or migraines annually
Purchase steps add friction when relief is needed most
"This isn't a niche inconvenience—it's a universal problem affecting billions of purchase occasions annually."
The Convergence of Three Powerful Trends
Market timing is everything. RedeDose arrives at the intersection of unprecedented consumer mobility, evolving purchasing behaviors, and regulatory modernization.
Record Travel Volume
3.08M TSA screenings in a single day (2024). Air travel continues to surge post-pandemic, creating unprecedented demand for portable, on-the-go solutions.
Shifting Consumer Behavior
83% of c-store purchases consumed within 1 hour. Consumers expect immediate, complete solutions. Convenience is no longer optional—it's essential.
Regulatory Tailwinds
2020 CARES Act modernized OTC process. FDA's updated monograph process streamlines the path to market for innovative products like RedeDose.
Complete Relief in One Package
RedeDose is the patented, single-use package that combines a standard OTC medication with a 3-ounce sip of purified water. One seamless motion delivers complete relief.
The Experience
Peel
Remove tamper-evident seal
Pop
Break child-resistant sachet
Twist
Open compact water compartment
Swallow
Experience complete relief
TSA-Compliant
3 oz liquid clears security
Tamper-Evident
Consumer safety first
Child-Resistant
FDA-compliant packaging
Full Labeling
Complete Drug Facts panel
Initial SKU Lineup
Pain Relief
Acetaminophen / Ibuprofen
Headaches, body aches
Allergy
Diphenhydramine
Seasonal allergies
Motion Sickness
Dimenhydrinate
Travel-related nausea
A $40B+ Market Ripe for Innovation
The U.S. over-the-counter medication market represents a massive, established opportunity with clear entry points for RedeDose's unique value proposition.
$40B+
U.S. OTC medication market with 3 billion+ annual purchase occasions
$30B
Single-serve packaging segment growing at 8-9% CAGR
7,600
First-wave target locations (airports, travel plazas, convenience stores)
3B+
Annual OTC purchase occasions in the U.S.
8-9%
Single-serve packaging CAGR
0.1%
Market capture = millions of units annually
Scalable Wholesale with Strong Unit Economics
RedeDose operates on a proven B2B2C wholesale model, selling to distributors and retail partners who restock continuously.
COGS
$0.50
Per unit at scale
Wholesale
$1.50
To distributors
Retail
$2.99
To $3.99 at premium
Gross Margin
67%
At scale (Year 3+)
De-Risked and Ready to Execute
Unlike most early-stage startups, RedeDose has systematically eliminated the major risk factors that typically concern investors.
IP Secured
5 issued utility patents (3 US, 1 EU, 1 AU) create a powerful legal barrier to entry
Product Ready
Finalized, shelf-ready prototypes complete and tested for immediate market launch
Regulatory Cleared
FDA labeler-of-record status secured (NDC Labeler Code: 87218)
Manufacturing Validated
COGS model confirmed with formal quotes for 250K and 1M unit production runs
RedeDose is not just an idea—it's a de-risked business ready to execute. Your capital funds growth, not uncertainty.
Phased Rollout to Validate and Scale
A disciplined, data-driven approach to market entry that progressively de-risks the business while building momentum.
Pilot Phase
Q1-Q2 2026
100+ Locations
Prove velocity, gather real-world sales data, refine positioning and merchandising
Regional Expansion
H2 2026
1,000+ Sites
Scale winning regions, optimize supply chain, build brand awareness
National Rollout
2027-2028
7,600 Sites
Full first-wave rollout, establish category leadership, prepare for Series A
Strong Growth with Clear Path to Profitability
Year 2
EBITDA Breakeven Achieved
68%
Peak Gross Margin by Year 3
120%
CAGR Years 1-4
Experienced Operators Ready to Execute
RedeDose is led by a seasoned team with deep domain expertise across healthcare, operations, commercial strategy, and regulatory affairs.
Howard Beader
CEO & Founder
Serial entrepreneur, healthcare executive
Rick Raisman
COO
Operations & supply chain expert
Steve Pear
CSO
Strategic advisor, M&A experience
Mark Leney
CCO
Commercial & sales leadership
Lori Bovarnick
CRO
Regulatory & compliance expert
100+
Combined Years of Industry Experience
5
Successful Exits Across Team Members
$500M+
Products Launched in Aggregate Revenue
Fuel Our Market Launch
We're raising a $3.0M Seed Round (priced equity or SAFE) to execute our go-to-market strategy and validate commercial traction.
$3.0M
Seed Round
Priced Equity or SAFE
18-24 Months Runway
Capital efficient path to key milestones
Use of Funds
Manufacturing & Inventory
$1.2M for first production run and working capital
Go-To-Market & Sales
$900K for distribution, merchandising, and marketing
Operations & Team
$600K for key hires and infrastructure
Contingency
$300K reserve for unforeseen needs
First Production Run
250K-500K units
1,000+ Retail Locations
Pilot and regional rollout
Proven Sales Velocity
Real-world data
Path to Series A
Position for growth
The Future of On-the-Go Wellness
We envision a world where relief is always within reach—where no one has to choose between convenience and complete care. RedeDose will become the ubiquitous solution for on-the-go medication, available wherever life takes you.
The market is ready. The product is proven. The team is assembled. Join us in building the future of convenient healthcare.
Peel. Pop. Twist. Swallow. Relief.